

## **“What’s New” Medical Pharmaceutical Policy August 2018 Updates**

### **MBP 176.0 Sublocade (buprenorphine ER subcutaneous injection)- New policy**

Sublocade (buprenorphine ER subcutaneous injection) will be considered medically necessary when ALL of the following criteria are met:

- Medical record documentation that the patient is 18 years of age or older **AND**
- Medical record documentation of a diagnosis of opioid use disorder (opioid dependence) **AND**
- Medical record documentation that member has been initiated into treatment with a transmucosal buprenorphine-containing product (e.g. Suboxone, buprenorphine/naloxone, buprenorphine), followed by dose adjustment for a minimum of 7 days **AND** until cravings and withdrawal symptoms are clinically controlled **AND**
- Medical record documentation that the member will not be receiving supplemental sublingual buprenorphine concurrently with Sublocade **AND**
- If the member has previously been established on Sublocade and the 300mg maintenance dose is requested: Medical record documentation that the member has tried and failed the 100mg maintenance dose **AND** that the benefits outweigh the risks of increasing to the 300mg maintenance dose **AND**
- Confirmation that the prescriber or prescriber’s delegate has conducted a review of Pennsylvania’s Prescription Drug Monitoring Program (PA PDMP) prior to administering Sublocade.

**AUTHORIZATION DURATION:** If approved, initial authorization duration will be for 3 months. After the initial 3-month authorization, subsequent approval will be for 12 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of the following:

- Medical record documentation that the member will not be receiving supplemental sublingual buprenorphine concurrently with Sublocade **AND**
- Medical record documentation of one of the following:
  - That the member will continue to receive the 100mg monthly maintenance dose **OR**
  - If 300mg maintenance dose is requested, the member has tried and failed the 100mg monthly maintenance dose **AND** the benefits outweigh the risks of receiving the 300mg monthly dose

**AND**

- Confirmation that the prescriber or prescriber’s delegate has conducted a review of Pennsylvania’s Prescription Drug Monitoring Program (PA PDMP) prior to administering Sublocade.

**QUANTITY LIMIT:**

- For 100mg dose: 1 syringe (0.5mL) per 28 days
- For 300mg dose: 1 syringe (1.5mL) per 28 days